Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 0904-6707

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 0904-6707). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label (42fefb90 6941 4539 8f32 Df1896223450 00)

Sevelamer Carbonate 800 mg film-coated tablets unit dose packaging label by Major Pharmaceuticals. The label includes the active ingredient Sevelamer carbonate at 800 mg per tablet, NDC 0904-6707-82, and directions referencing an insert for dosage and warnings. It also indicates the product is Rx only and contains 100 tablets. The label details storage instructions and manufacturer/distributor information.*

FDA Label Image

Carton Label (42fefb90 6941 4539 8f32 Df1896223450 01)

Sevelamer Carbonate 800 mg film-coated tablets unit dose packaging label from Major Pharmaceuticals. The label includes the proprietary and generic name, strength, quantity of 50 tablets, and storage instructions. It also states the product is prescription only and provides distributor and manufacturer information along with the NDC 0904-6707-06.*

FDA Label Image

Figure1 (Figure1)

Chemical structure of the active ingredient Sevelamer Carbonate, illustrating the polymeric amine backbone with ammonium and bicarbonate ions indicated in the structure.*

FDA Label Image

Figure2 (Figure2)

A line graph showing the relationship between reduction in serum phosphorus (mg/dL) on the x-axis and the percentage of patients with a reduction 2 times or greater on the y-axis. Two lines represent data for Sevelamer Hydrochloride and an Active Control, depicting the comparative effectiveness in reducing serum phosphorus levels over a range of values.*

FDA Label Image

Figure3 (Figure3)

A line graph depicting phosphate change from baseline over a 52-week study period, comparing Sevelamer Hydrochloride and an active control. The x-axis represents study weeks from 0 to 52, and the y-axis shows phosphate change values. Two lines represent the treatment groups, showing trends over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.